DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 hours ago

ALNY·Alnylam Pharmaceuticals, Inc.

$.
+. (+.%)
After Hours
High
$275.58
Open
$269.15
Market Cap
36.28B
52W High
$495.55
Low
$265.64
P. Close
$271.77
P/E
62.86
52W Low
$262.21
Fwd P/E
20.22
DailyIQ Est.
$456.21
Technical Score (1D)
27
SELL
News Sentiment
66
BULLISH
Analysts are divided on whether Alnylam will beat earnings expectations in its upcoming report, with one view citing a lack of key ingredients for a beat and another projecting modest revenue and EPS growth. The divergence stems from differing assessments of the company’s RNAi pipeline, where some see limited upside while others highlight growth potential in flagship products, creating short‑term pricing uncertainty. Traders should watch the earnings release for any surprise in revenue projections or guidance revisions that could resolve this ambiguity. JP Morgan’s recent downgrade of the price target to $400, despite maintaining an Overweight rating, signals caution about near‑term earnings and competitive pressures. Morgan Stanley’s simultaneous lift of the target to $400 from $370 reflects confidence in pipeline data and regulatory outlook, underscoring the split analyst sentiment. Alnylam’s strong cash reserves and GAAP profitability provide a buffer that could support continued R&D investment and cushion against market volatility. The company’s neuroscience pipeline has advanced with the initiation of a global Phase 2 study of mivelsiran for Down‑syndrome‑associated Alzheimer’s and completion of enrollment in a cerebral amyloid angiopathy trial, potentially broadening its therapeutic reach. Upcoming enrollment milestones and interim safety data from these studies will be key to gauge future product prospects and could influence valuation. Finally, the Q2 2026 webcast scheduled for July 30 will deliver the definitive revenue outlook for 2026, making it a critical event for assessing whether Alnylam can sustain its recent growth trajectory.
Earnings Summary
Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNA interference therapeutics, markets approved products such as ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio while advancing a pipeline that targets hemophilia, hypertension, and amyloidosis. Operating in the healthcare biotechnology sector, the firm relies on collaborations with Regeneron and Roche to accelerate development. In its most recent earnings cycle, Alnylam reported a Q4 2024 EPS of $0.06 versus an estimate of –$0.1411, a modest beat, while revenue of $593.2 M matched expectations; the following quarter, Q4 2025, saw an EPS of $1.25 against an estimate of $2.2088, a miss, and revenue of $1.097 B versus an estimate of $1.139 B, a slight shortfall. The latest quarter, Q1 2026, delivered an EPS of $1.99 against an estimate of $0.9524, a strong beat, and revenue of $1.167 B versus an estimate of $1.136 B, a 6.5 % YoY increase from the prior year’s Q1. Historically, Alnylam’s revenue surged from $593 M in Q4 2024 to $1.097 B in Q4 2025, an 85 % YoY jump, before modestly rising to $1.167 B in Q1 2026; EPS has alternated between beats and misses, with a notable miss in Q4 2025 after two consecutive beats, suggesting volatility in earnings momentum despite robust revenue growth. Recent news indicates that the company will webcast its Q2 2026 results on July 30, with analysts noting a modest upside in revenue and EPS but expressing uncertainty about pipeline progress; a price‑target cut by JPMorgan to $400 reflects concerns over competitive pressure and earnings trajectory, while other analysts maintain an overweight stance, underscoring divergent views. Investors should watch the Q2 2026 earnings call for updates on pipeline milestones, particularly the status of mivelsiran and other late‑stage programs, as well as regulatory feedback that could materially alter the company’s outlook; monitoring cost‑control measures, capital‑expenditure plans, and any guidance revisions will also be key, as these factors will determine whether Alnylam can sustain its revenue gains and translate them into consistent earnings performance.

EPS

EstBeatMiss
$-0.49$0.27$1.03$1.80$2.56Q4'24Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.16 - -
Q1'26$0.95$1.99+108.9%
Q4'25$2.21$1.25-43.4%
Q4'24$-0.14$0.06+142.5%

Revenue

EstBeatMiss
$480M$725M$969M$1.2B$1.5BQ4'24Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.3B - -
Q1'26$1.1B$1.2B+2.7%
Q4'25$1.1B$1.1B-3.7%
Q4'24 - $593M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ALNY Stock Snapshot

ALNY is currently trading at $271.40, giving Alnylam Pharmaceuticals, Inc. a market cap of 36.28B and a P/E ratio of 62.9. Today's range spans $265.64–$275.58, with shares opening at $269.15 and moving down $0.37 (0.1%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 66/100.

Over the past year ALNY has traded between $262.21 and $495.55 - the current price is +3.5% off the 52-week low and -45.2% from the high. 40 analysts cover the stock with a Buy consensus and a mean 12-month target of $432.04 (range $285.00–$551.00), implying upside of +59.2%.

Earnings estimate risk is at the forefront for Alnylam Pharmaceuticals, Inc. (ALNY) - a large-cap Healthcare name (36.28B market cap) showing a SELL (27/100) alongside bullish sentiment (66/100) often flags a period where consensus estimates are still catching down to what the market is already pricing in. Price: $271.40 (near 52-week lows in $262.21–$495.55). (P/E: 62.9) Active managers who track the technical-fundamental gap tend to position ahead of the revision, not after it.

The current SELL phase for ALNY (27/100) at $271.40 (near 52-week lows) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 66/100 (bullish) confirms that news flow is not providing a counternarrative. At 36.28B in Healthcare capitalization, ALNY has the liquidity for institutional exits to be orderly — but orderly doesn't mean shallow within the $262.21–$495.55 range.